Cereglide 71 is a next-generation intermediate catheter equipped with TruCourse Technology, which enhances the flexibility of the device, to help physicians with improved navigation and access to clots, even in challenging anatomical conditions
Cereglide 71 Intermediate Catheter with TruCourse technology. (Credit: Medical Device Business Services)
Cerenovus, a part of Johnson & Johnson MedTech, has introduced the Cereglide 71 Intermediate Catheter for the revascularisation of patients suffering from acute ischemic stroke.
Cereglide 71 is a next-generation intermediate catheter equipped with TruCourse Technology, which enhances the flexibility of the revascularisation device.
The intermediate catheter is designed to help physicians with improved navigation and access to clots, even in challenging anatomical conditions.
It is optimised for effective direct aspiration and delivery of compatible stent retrievers, including the EMBOTRAP III revascularisation device, into the patient’s neurovasculature.
The Cereglide 71 Intermediate Catheter with TruCourse provides physicians with optimal compatibility, delivery, and trackability during thrombectomy procedures, said Cerenovus.
Cerenovus worldwide president Mark Dickinson said: “Cereglide 71 Intermediate Catheter is specifically designed to glide through challenging anatomical conditions.
“Developed through robust research and clinical insights, our team designed a catheter for physicians that addresses unmet clinical needs by providing reliable trackability, durable delivery and the versatility for both direct aspiration and stent-retriever use – even in the most challenging anatomical conditions.”
The Cereglide 71 Intermediate Catheter is the latest advancement in the company’s planned Cereglide family of catheters and is part of its Cerenovus Stroke Solutions portfolio.
Cerenovus developed the devices within its Cerenovus Stroke Solutions portfolio using expert insights into stroke science from its Neuro Thromboembolic Initiative (NTI).
As part of ongoing sustainability efforts, Cereglide 71 Intermediate Catheter will use electronic instructions for use (e-IFUs).
The e-IFUs would help reduce environmental footprint, lower CO2 emissions during shipment and reduce post-consumer recycling and medical waste disposal of the healthcare systems.
Cerenovus intends to include Cereglide 71 in the next-phase CERENOVUS EXCELLENT Registry, focused on stroke-inducing blood clot removal by mechanical thrombectomy.
Westchester Medical Centre neuroendovascular surgery fellowship director, interventional neurologist Fawaz Al-Mufti said: “In the rapidly evolving landscape of neuroendovascular stroke care, staying on the cutting edge is crucial for advancing the field and ensuring physicians have the tools to navigate complex patient anatomy.
“Balancing trackability, support, and aspiration efficacy is crucial in overcoming the challenges of swift clot access during endovascular thrombectomy. As the global first user, in initial use, Cereglide 71 Intermediate Catheter does just that.
“It impressively navigates, accesses occlusion sites, and engages with effectiveness to aspirate clots, rapidly restoring blood flow in the patient’s brain – potentially a life-saving intervention.”